Request Demo
Last update 07 Feb 2026
Docetaxel albumin bound
Last update 07 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Albumin-bound docetaxel, Nab-docetaxel, ABI-008 + [4] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Related
26
Clinical Trials associated with Docetaxel albumin boundCTR20254224
一项注射用多西他赛（白蛋白结合型）联合奥沙利铂和5-FU/LV（ADOF）一线治疗HER2中低表达或不表达，PD-L1 CPS<5的晚期胃/胃食管结合部腺癌的Ib/Ⅲ期研究 （DAWN研究）（仅开展Ib期）
[Translation] A Phase Ib/III study of docetaxel (albumin-bound) injection combined with oxaliplatin and 5-FU/LV (ADOF) as the first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma with low or no HER2 expression and PD-L1 CPS <5 (DAWN study) (Phase Ib only)
NCT07116824
A Phase II Trial to Evaluate the Safety and Efficacy of HB1801 Combination Therapy as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
ChiCTR2500112147
A Phase Ib study (DAWN study) on the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with low or no expression of HER2 and PD-L1 CPS<5 using docetaxel (albumin-bound) for injection combined with oxaliplatin and 5-FU/LV (ADOF)
100 Clinical Results associated with Docetaxel albumin bound
Login to view more data
100 Translational Medicine associated with Docetaxel albumin bound
Login to view more data
100 Patents (Medical) associated with Docetaxel albumin bound
Login to view more data
100 Deals associated with Docetaxel albumin bound
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Phase 3 | - | 12 Aug 2024 | |
| Pancreatic adenocarcinoma | Phase 3 | China | 29 Jul 2024 | |
| Squamous non-small cell lung cancer | Phase 3 | - | 01 May 2024 | |
| Gastroesophageal junction adenocarcinoma | Phase 3 | China | 15 Mar 2024 | |
| stomach adenocarcinoma | Phase 3 | China | 15 Mar 2024 | |
| Stomach Cancer | Phase 3 | China | 27 Feb 2024 | |
| HER2 Positive Breast Cancer | Phase 3 | China | 23 Jul 2023 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | - | 15 Sep 2025 | |
| Advanced breast cancer | Phase 2 | China | 01 Aug 2025 | |
| Advanced gastric carcinoma | Phase 2 | China | 04 Jun 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 40 | Glumetinib + albumin-bound docetaxel (HB1801) (MET 3+) | xkvgaonleg(pmgbossaqx) = One dose-limiting toxicity (grade 4 neutropenia) occurred at 75 mg/m2 vldvfyxxfm (egjiosveit ) View more | Positive | 05 Dec 2025 | ||
Glumetinib + albumin-bound docetaxel (HB1801) (MET 2+) | |||||||
Phase 2 | 128 | xskghcqabp(sgpduqjmxs) = uwaivbqwbf dqlzvlsboo (eniuchobeq, 2.8 - 4.2) View more | Positive | 23 Jan 2025 | |||
xskghcqabp(sgpduqjmxs) = ppelqscimx dqlzvlsboo (eniuchobeq, 1.8 - 3.0) View more | |||||||
NCT04931823 (ASCO2024) Manual  | Phase 1 | 34 | pgfhxjwpud(khatyaykhk) = nkwkiqwjcs mwohfiysmh (pblcbsooht ) View more | Positive | 24 May 2024 | ||
NCT05705635 (ASCO2024) Manual | Phase 2 | 125 | HB1801 (albumin-bound docetaxel) | igkqnbwvye(eztivfnzxa) = ngsuleeqfq nddztegfjy (oyrvtyinoz, 12.88 - 39.54) View more | Positive | 24 May 2024 | |
docetaxel (Taxotere) | igkqnbwvye(eztivfnzxa) = wanxkjjqrm nddztegfjy (oyrvtyinoz, 6.20 - 28.31) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free